Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease.

The trials did not confirm the superiority of semaglutide versus placebo in the reduction of progression of Alzheimer’s disease, as measured by the change in Clinical Dementia Rating, Sum of Boxes (CDR-SB) score compared to baseline.

The decision to pursue an Alzheimer’s disease indication with semaglutide was based on real-world evidence studies, preclinical models, as well as post-hoc analyses from diabetes and obesity trials.

Also Read: Novo ...